title: [How should hormone therapy for castration-resistant prostate cancer be continued?].
abstract: After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but still androgen-sensitive tumor growth. Our understanding and the treatment of such castration-resistant prostate cancer has changed markedly. The introduction of new drugs like abiraterone and MDV3100 has shown that prostate cancer progression even in the"hormone-refractory" stage is driven by androgen receptor signaling. Based on this information the question of whether androgen deprivation therapy in castration-resistant prostate cancer should be continued or not is still of relevance. This review gives a critical overview of the literature and current guideline recommendations.
authors.affiliation: Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinik Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Deutschland. Spahn_M@klinik.uni-wuerzburg.de
authors.forename: M
authors.initials: M
authors.lastname: Spahn
authors.forename: M
authors.initials: M
authors.lastname: Krebs
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002369:Castration; D003131:Combined Modality Therapy; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D017211:Treatment Failure
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D004965:Estrogen Antagonists